Recent advances in the pharmacotherapy of schizophrenia.

Abstract

The major advance in the psychopharmacology of schizophrenia has been the rediscovery of clozapine and the development of other novel antipsychotic drugs, all of which are superior to typical neuroleptic drugs with regard to extrapyramidal symptoms. Clozapine, the best studied of these agents, is also superior in efficacy with regard to psychopathology and cognitive function and has been shown not to cause tardive dyskinesia. A variety of other novel agents, e.g., risperidone, olanazpine, amperozide, seroquel, sertindole, zaprisidone and melperone, must be further studied to establish their efficacy relative to clozapine or the typical neuroleptics, or both. It is likely that these novel agents will displace the typical neuroleptic drugs as the primary treatment of schizophrenia.

• Authors: H Y Meltzer, M A Lee, R Ranjan
• Journal: Acta psychiatrica Scandinavica. Supplementum (Acta Psychiatr Scand Suppl) Vol. 384 Pg. 95-101 ( 1994) ISSN: 0065-1591 [Print] Denmark
• PMID: 7533472 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Antipsychotic Agents
• Isoxazoles
• Piperidines
• Clozapine
• Risperidone
• Dopamine

Topics

• Adult
• Antipsychotic Agents
• Brain (physiopathology)
• Clozapine (economics, pharmacology, therapeutic use)
• Dopamine (metabolism)
• Humans
• Isoxazoles (economics, pharmacology, therapeutic use)
• Piperidines (economics, pharmacology, therapeutic use)
• Risperidone
• Schizophrenia (drug therapy, physiopathology)